Key Takeaways
- • HIG Capital has completed the $1.8bn sale of Celerion Holdings to THL Partners-affiliated funds, representing a significant realisation from its Advantage investment strategy focused on monetising mature mid-market healthcare assets.
- • Celerion, a clinical research organisation providing early-stage drug development and trial services across North America, Europe, and Asia, was a core healthcare services holding within HIG's portfolio and demonstrates strong exit momentum in resilient sectors.
- • This transaction is part of a broader acceleration of capital returns by HIG, which has completed over $4.5bn in combined enterprise value exits since late 2025, including St. Croix and United Flow Technologies, as private equity firms capitalise on improving M&A sentiment.
- • The deal reflects strengthening exit momentum across private equity despite an uneven transaction environment, driven by improved market conditions and LP demand for accelerated distributions following a period of constrained dealmaking.
- • HIG Capital, managing approximately $75bn in assets across buyouts, credit, real estate, and infrastructure strategies, continues its operational value-creation approach focused on building scale in established mid-market businesses through active management and transformation initiatives.
Summary
HIG Capital has successfully exited its investment in Celerion Holdings through the sale to funds affiliated with THL Partners, completing a $1.8bn transaction that underscores selective but strengthening momentum in private equity realisations. Celerion, a clinical research organisation specialising in early-stage clinical trial and drug development services, represented a core healthcare services asset within HIG's portfolio, operating across North America, Europe, and Asia to support pharmaceutical and biotech companies from first-in-human studies through proof-of-concept trials.
The Celerion sale marks the latest completion under HIG's Advantage investment strategy, which has demonstrated substantial exit velocity in recent months. Combined with prior disposals of St. Croix and United Flow Technologies, these transactions have generated over $4.5bn in combined enterprise value since late 2025, reflecting a sustained and deliberate push to monetise mature portfolio companies and return capital to investors. This acceleration comes at a time when limited partners have increasingly pressed for capital distributions following a prolonged period of constrained exit channels and slower dealmaking activity.
The transaction is emblematic of broader market dynamics reshaping private equity activity. Improved sentiment in select M&A segments, particularly for high-quality assets in resilient sectors such as healthcare services, has contributed to a modest but notable recovery in realisation activity. Healthcare services, as a relatively defensive and essential sector, continues to attract institutional buyers even amid broader economic uncertainty. HIG's operational value-creation playbook—which emphasises building scale in mid-market businesses through active management and targeted transformation initiatives—has evidently resonated with strategic and financial acquirers seeking operationally strengthened platforms.
HIG Capital, managing approximately $75bn in assets across buyouts, credit, real estate, and infrastructure strategies globally, continues to position itself as an operator-focused investor with a disciplined approach to portfolio exits. The Celerion transaction demonstrates that despite a still-uneven transaction environment, selective exit momentum is building for quality assets with resilient business models, supporting the firm's narrative of disciplined capital deployment and performance realisation across its diversified platform.
The Celerion sale marks the latest completion under HIG's Advantage investment strategy, which has demonstrated substantial exit velocity in recent months. Combined with prior disposals of St. Croix and United Flow Technologies, these transactions have generated over $4.5bn in combined enterprise value since late 2025, reflecting a sustained and deliberate push to monetise mature portfolio companies and return capital to investors. This acceleration comes at a time when limited partners have increasingly pressed for capital distributions following a prolonged period of constrained exit channels and slower dealmaking activity.
The transaction is emblematic of broader market dynamics reshaping private equity activity. Improved sentiment in select M&A segments, particularly for high-quality assets in resilient sectors such as healthcare services, has contributed to a modest but notable recovery in realisation activity. Healthcare services, as a relatively defensive and essential sector, continues to attract institutional buyers even amid broader economic uncertainty. HIG's operational value-creation playbook—which emphasises building scale in mid-market businesses through active management and targeted transformation initiatives—has evidently resonated with strategic and financial acquirers seeking operationally strengthened platforms.
HIG Capital, managing approximately $75bn in assets across buyouts, credit, real estate, and infrastructure strategies globally, continues to position itself as an operator-focused investor with a disciplined approach to portfolio exits. The Celerion transaction demonstrates that despite a still-uneven transaction environment, selective exit momentum is building for quality assets with resilient business models, supporting the firm's narrative of disciplined capital deployment and performance realisation across its diversified platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.